John Theurer Cancer Center Partnership Tour

Published: Monday, Dec 19, 2011

The John Theurer Cancer Center (JTCC), at Hackensack University Medical Center in New Jersey, is one of the largest cancer facilities in the US; it ranks 5th in patient volume and is dedicated to personalized cancer care.

The new $130-million, 155,000-square-foot, freestanding comprehensive facility offers some of the most up-to-date treatments and technologies in the country.

The photos provide a glimpse into the newly designed standalone cancer center. Dr. Andrew Pecora, Chief Innovations Officer, Professor and Vice President of Cancer Services, led an introduction and overview of the new facility. Dr. Andre Goy, Chairman and Director and Chief of the Division of Lymphoma, followed with a discussion on the latest advances in oncology research. The tour provided a look into the roles of the oncology nurse navigator, pharmacist, radiation therapist, researcher, pathologist, social worker, and registered dietitian.
The John Theurer Cancer Center (JTCC), at Hackensack University Medical Center in New Jersey, is one of the largest cancer facilities in the US; it ranks 5th in patient volume and is dedicated to personalized cancer care.

The new $130-million, 155,000-square-foot, freestanding comprehensive facility offers some of the most up-to-date treatments and technologies in the country.

The photos provide a glimpse into the newly designed standalone cancer center. Dr. Andrew Pecora, Chief Innovations Officer, Professor and Vice President of Cancer Services, led an introduction and overview of the new facility. Dr. Andre Goy, Chairman and Director and Chief of the Division of Lymphoma, followed with a discussion on the latest advances in oncology research. The tour provided a look into the roles of the oncology nurse navigator, pharmacist, radiation therapist, researcher, pathologist, social worker, and registered dietitian.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x